• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

检测不同的患者总体评估阈值在类风湿关节炎缓解定义中的应用:当前的 ACR/EULAR 二分类标准是否最优?

Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?

机构信息

Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Wien, Austria.

Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA.

出版信息

Ann Rheum Dis. 2020 Apr;79(4):445-452. doi: 10.1136/annrheumdis-2019-216529. Epub 2020 Feb 5.

DOI:10.1136/annrheumdis-2019-216529
PMID:32024651
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10564460/
Abstract

OBJECTIVES

This study aimed to evaluate different patient global assessment (PGA) cut-offs required in the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Boolean remission definition for their utility in rheumatoid arthritis (RA).

METHODS

We used data from six randomised controlled trials in early and established RA. We increased the threshold for the 0-10 score for PGA gradually from 1 to 3 in steps of 0.5 (Boolean1.5 to Boolean3.0) and omitted PGA completely (BooleanX) at 6 and 12 months. Agreement with the index-based (Simplified Disease Activity Index (SDAI)) remission definition was analysed using kappa, recursive partitioning (classification and regression tree (CART)) and receiver operating characteristics. The impact of achieving each definition on functional and radiographic outcomes after 1 year was explored.

RESULTS

Data from 1680 patients with early RA and 920 patients with established RA were included. The proportion of patients achieving Boolean remission increased with higher thresholds for PGA from 12.4% to 19.7% in early and 5.9% to 12.3% in established RA at 6 months. Best agreement with SDAI remission occurred at PGA cut-offs of 1.5 and 2.0, while agreement decreased with higher PGA (CART: optimal agreement at PGA≤1.6 cm; sensitivity of PGA≤1.5 95%). Changing PGA thresholds at 6 months did not affect radiographic progression at 12 months (mean ꙙsmTSS for Boolean, 1.5, 2.0, 2.5, 3.0, BooleanX: 0.35±5.4, 0.38±5.14, 0.41±5.1, 0.37±4.9, 0.34±4.9, 0.27±4.7). However, the proportion attaining HAQ≤0.5 was 90.2%, 87.9%, 85.2%, 81.1%, 80.7% and 73.1% for the respective Boolean definitions.

CONCLUSION

Increasing the PGA cut-off to 1.5 cm would provide high consistency between Boolean with the index-based remission; the integer cut-off of 2.0 cm performed similarly.

摘要

目的

本研究旨在评估美国风湿病学会/欧洲抗风湿病联盟(ACR/EULAR)中不同患者整体评估(PGA)截断值在类风湿关节炎(RA)中的应用价值。

方法

我们使用了六项早期和晚期 RA 随机对照试验的数据。我们逐渐将 PGA 的 0-10 评分的阈值从 1 提高到 3,步长为 0.5(Boolean1.5 到 Boolean3.0),并在 6 个月和 12 个月时完全省略 PGA(BooleanX)。使用 Kappa、递归分区(分类和回归树(CART))和接收器操作特征分析与基于指数的(简化疾病活动指数(SDAI))缓解定义的一致性。探讨了在 1 年后达到每个定义对功能和放射学结果的影响。

结果

共纳入了 1680 例早期 RA 和 920 例晚期 RA 患者的数据。PGA 阈值越高,达到 Boolean 缓解的患者比例越高,早期 RA 从 12.4%增加到 19.7%,晚期 RA 从 5.9%增加到 12.3%,在 6 个月时。PGA 截断值为 1.5 和 2.0 时与 SDAI 缓解的一致性最佳,而随着 PGA 增加,一致性降低(CART:PGA≤1.6cm 时最佳一致性;PGA≤1.5 的敏感性为 95%)。6 个月时 PGA 阈值的改变并不影响 12 个月时的放射学进展(平均ꙙsmTSS for Boolean、1.5、2.0、2.5、3.0、BooleanX:0.35±5.4、0.38±5.14、0.41±5.1、0.37±4.9、0.34±4.9、0.27±4.7)。然而,各自的 Boolean 定义中,达到 HAQ≤0.5 的比例分别为 90.2%、87.9%、85.2%、81.1%、80.7%和 73.1%。

结论

将 PGA 截断值提高到 1.5cm 将为 Boolean 与基于指数的缓解之间提供高度一致性;整数截断值 2.0cm 表现相似。

相似文献

1
Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?检测不同的患者总体评估阈值在类风湿关节炎缓解定义中的应用:当前的 ACR/EULAR 二分类标准是否最优?
Ann Rheum Dis. 2020 Apr;79(4):445-452. doi: 10.1136/annrheumdis-2019-216529. Epub 2020 Feb 5.
2
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.美国风湿病学会/欧洲抗风湿病联盟类风湿关节炎缓解标准:2022 年修订版。
Ann Rheum Dis. 2023 Jan;82(1):74-80. doi: 10.1136/ard-2022-223413. Epub 2022 Oct 24.
3
American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision.美国风湿病学会/欧洲抗风湿病联盟类风湿关节炎缓解标准:2022 年修订版。
Arthritis Rheumatol. 2023 Jan;75(1):15-22. doi: 10.1002/art.42347. Epub 2022 Oct 23.
4
Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points.比较评估不同的美国风湿病学会/欧洲抗风湿病联盟缓解标准在类风湿关节炎临床试验终点中的应用。
Arthritis Rheumatol. 2017 Mar;69(3):518-528. doi: 10.1002/art.39945.
5
Remission in rheumatoid arthritis: a comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease activity index-5, a patient self-report disease activity index.类风湿关节炎缓解:新提出的 ACR/EULAR 缓解标准与类风湿关节炎疾病活动指数-5(一种患者自我报告的疾病活动指数)的比较。
J Rheumatol. 2013 Apr;40(4):394-400. doi: 10.3899/jrheum.120952. Epub 2013 Feb 1.
6
Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab.患者索引数据3的常规评估以及美国风湿病学会/欧洲抗风湿病联盟临时缓解定义作为托珠单抗类风湿关节炎临床试验中影像学结果的预测指标
Arthritis Care Res (Hoboken). 2017 May;69(5):609-615. doi: 10.1002/acr.23008. Epub 2017 Apr 7.
7
Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions.接近 ACR/EULAR 缓解标准的漏诊:患者整体评估在布尔和基于指数定义中的影响。
Ann Rheum Dis. 2012 Oct;71(10):1702-5. doi: 10.1136/annrheumdis-2012-201519. Epub 2012 Jun 26.
8
Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission.类风湿关节炎患者达到 DAS、SDAI 或 CDAI 缓解但未达到布尔缓解时疾病活动度测量的差异。
Semin Arthritis Rheum. 2020 Apr;50(2):276-284. doi: 10.1016/j.semarthrit.2019.09.005. Epub 2019 Sep 19.
9
Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?缓解定义指导类风湿关节炎的免疫抑制治疗:哪种最适合该目的?
RMD Open. 2024 Mar 4;10(1):e003972. doi: 10.1136/rmdopen-2023-003972.
10
Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.重新审视排除患者整体评估后使用缓解标准治疗类风湿关节炎:对 5792 名患者的个体荟萃分析。
Ann Rheum Dis. 2021 Mar;80(3):293-303. doi: 10.1136/annrheumdis-2020-217171. Epub 2020 Oct 6.

引用本文的文献

1
Persistently different patterns of patient's global assessment of health in rheumatoid arthritis are associated with pain and impaired function more than with inflammation: an inception cohort study over 15 years.类风湿关节炎患者整体健康评估的持续不同模式与疼痛和功能受损的关联大于与炎症的关联:一项为期15年的初始队列研究
RMD Open. 2025 Jan 21;11(1):e004744. doi: 10.1136/rmdopen-2024-004744.
2
Remission versus low disease activity as treatment targets in rheumatoid arthritis: how to strike the right balance between too strict and too lenient targets? A meta-epidemiological study of individual patient data.缓解与低疾病活动度作为类风湿关节炎的治疗目标:如何在过于严格和过于宽松的目标之间取得恰当平衡?一项基于个体患者数据的荟萃流行病学研究。
RMD Open. 2024 Nov 7;10(4):e004387. doi: 10.1136/rmdopen-2024-004387.
3

本文引用的文献

1
Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.48 周时对应答不足的患者转换为替代治疗,对比乌帕替尼或阿达木单抗加甲氨蝶呤治疗类风湿关节炎患者 48 周的安全性和有效性。
Ann Rheum Dis. 2019 Nov;78(11):1454-1462. doi: 10.1136/annrheumdis-2019-215764. Epub 2019 Jul 30.
2
Impact of Patient's Global Assessment on Achieving Remission in Patients With Rheumatoid Arthritis: A Multinational Study Using the METEOR Database.患者整体评估对类风湿关节炎患者缓解的影响:使用 METEOR 数据库的多国研究。
Arthritis Care Res (Hoboken). 2019 Oct;71(10):1317-1325. doi: 10.1002/acr.23866.
3
Management strategies in rheumatoid arthritis.类风湿关节炎的治疗策略。
Nat Rev Rheumatol. 2024 Dec;20(12):760-769. doi: 10.1038/s41584-024-01169-7. Epub 2024 Oct 24.
4
Comparison of Remission Criteria in Patients with Rheumatoid Arthritis: Results from a Smart System of Disease Management Group.类风湿关节炎患者缓解标准的比较:疾病管理智能系统组的结果
J Inflamm Res. 2024 Oct 11;17:7183-7193. doi: 10.2147/JIR.S472549. eCollection 2024.
5
Application of disease activity index in rheumatoid arthritis management in Korea.疾病活动指数在韩国类风湿关节炎管理中的应用。
J Rheum Dis. 2024 Oct 1;31(4):193-199. doi: 10.4078/jrd.2024.0077. Epub 2024 Aug 2.
6
Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?缓解定义指导类风湿关节炎的免疫抑制治疗:哪种最适合该目的?
RMD Open. 2024 Mar 4;10(1):e003972. doi: 10.1136/rmdopen-2023-003972.
7
The impact of time length to Boolean remission for tight disease activity control after acquisition in rheumatoid arthritis patients.在类风湿关节炎患者获得缓解后,时间长度对严格疾病活动控制达到布尔缓解的影响。
Sci Rep. 2023 Aug 25;13(1):13908. doi: 10.1038/s41598-023-39711-4.
8
RheuMetric Quantitative 0 to 10 Physician Estimates of Inflammation, Damage, and Distress in Rheumatoid Arthritis: Validation Against Reference Measures.类风湿关节炎中炎症、损伤和痛苦的RheuMetric定量0至10分医生评估:与参考指标的验证
ACR Open Rheumatol. 2023 Oct;5(10):511-521. doi: 10.1002/acr2.11574. Epub 2023 Aug 22.
9
Disease activity and disease-related factors are drivers of patient global assessment in rheumatoid arthritis: a real-life cross-sectional study.疾病活动度和与疾病相关的因素是类风湿关节炎患者总体评估的驱动因素:一项真实世界的横断面研究。
Rheumatol Int. 2023 Oct;43(10):1885-1895. doi: 10.1007/s00296-023-05383-6. Epub 2023 Jul 16.
10
Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study.类风湿关节炎复合疾病活动指数中性别差异影响的综合评估:一项全国性观察性队列研究的结果
BMC Rheumatol. 2023 Mar 21;7(1):4. doi: 10.1186/s41927-023-00328-9.
Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity.
类风湿关节炎活动度患者与医生整体评估之间关系的潜在剖面分析方法
RMD Open. 2018 Jun 28;4(1):e000695. doi: 10.1136/rmdopen-2018-000695. eCollection 2018.
4
Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.早期类风湿关节炎达标治疗 6 个月后的临床和超声缓解:与未来良好的放射学和身体结局的关联。
Ann Rheum Dis. 2018 Oct;77(10):1421-1425. doi: 10.1136/annrheumdis-2017-212830. Epub 2018 Jun 22.
5
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.乌帕替尼治疗对常规合成改善病情抗风湿药物应答不足的类风湿关节炎患者的安全性和疗效(SELECT-NEXT):一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.
6
Physician global assessments for disease activity in rheumatoid arthritis are all over the map!医生对类风湿性关节炎疾病活动的整体评估结果差异极大!
RMD Open. 2018 Feb 21;4(1):e000578. doi: 10.1136/rmdopen-2017-000578. eCollection 2018.
7
Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition.评估类风湿关节炎患者在抑制IL-6通路后,针对28个关节疾病活动评分(DAS28)新提出的缓解切点。
Arthritis Res Ther. 2017 Jul 4;19(1):155. doi: 10.1186/s13075-017-1346-5.
8
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.托法替布单药治疗、托法替布联合甲氨蝶呤与阿达木单抗联合甲氨蝶呤治疗类风湿关节炎患者的疗效和安全性(ORAL Strategy):一项 IIIb/IV 期、双盲、头对头、随机对照临床试验。
Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.
9
Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.患者报告结局的中心间差异低于类风湿关节炎客观活动指标:一项横断面研究。
Rheumatology (Oxford). 2017 Aug 1;56(8):1395-1400. doi: 10.1093/rheumatology/kex076.
10
Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change.抑制类风湿关节炎炎症:患者整体评估是否模糊了目标?基于实践的范式转变呼吁。
Arthritis Care Res (Hoboken). 2018 Mar;70(3):369-378. doi: 10.1002/acr.23284. Epub 2018 Jan 30.